Otoactive Compounds and Targets for Hearing Health

A computational analysis of thousands of scientific papers has mapped the chemical landscape of drugs that can harm or protect hearing. The work, led by Aylin del Moral-Morales, Jean Arguello‐Camarillo, and Jesús Yael Castañón Bello, identified 1,758 such compounds, creating a public resource to tackle drug-induced hearing loss.

Mining the Literature with AI

The scale of published research on drug-related hearing damage made a traditional review impossible. The team developed an automated Python workflow to retrieve and process 7,801 abstracts from PubMed. They then used GPT-4 as a precision tool to extract specific compound names and their explicitly stated roles—whether they were ototoxic (causing damage) or otoprotective (preventing it).

This large language model (LLM) approach avoided guesswork, focusing only on what was directly reported in the text. Each identified compound was then enriched with structural data from PubChem and cross-referenced with known drug-protein interactions from the BindingDB database. The final step was constructing a detailed network to see how these drugs interact with biological targets in the ear.

A Registry of 1,758 Otoactive Compounds

The results provide the first large-scale, systematic map of chemicals that act on the auditory system. The AI identified 1,758 otoactive small molecules. Within that total, 1,092 were flagged as ototoxic and 619 as otoprotective, with some compounds having complex, context-dependent roles.

Well-known offenders like the antibiotic class aminoglycosides and the chemotherapy agent cisplatin were confirmed. More importantly, the method surfaced many less-discussed compounds, expanding the known universe of potential risks and protective agents. This broad inventory is a foundational step for future safety studies.

ABCC3, ABCC4, and Albumin Emerge as Key Hubs

Network analysis of the ototoxic compounds revealed critical interaction points. The transporters ABCC3 and ABCC4, along with the blood protein albumin, appeared as central hubs. This finding suggests these proteins play an outsized role in how ototoxic drugs are moved and processed in the body, potentially influencing their damaging effects on hair cells in the inner ear.

Understanding these hubs offers new directions for research. For instance, could modulating the activity of ABCC3 or ABCC4 help shield the ear during necessary but toxic treatments like cisplatin chemotherapy? This mechanistic insight moves the field beyond simple catalogs of bad actors toward understanding how the damage occurs.

A Public Tool for Researchers and Clinicians

All data from this study is organized and freely accessible through an interactive web application at https://ototoxdb.streamlit.app. This database allows scientists to screen compounds, explore drug-target interactions, and download datasets for their own work.

For clinicians, this registry serves as a growing reference to understand the ototoxic potential of medications beyond the classic examples. It also highlights candidates for otoprotective co-therapies. This is particularly relevant in fields like oncology, where preserving quality of life during treatment is a major concern. The database will be updated as new literature is published, acting as a living surveillance system.

Implications for Hearing Health and Beyond

This research establishes a framework for ongoing, automated monitoring of drug-related hearing risks. It supports the development of protective strategies for patients requiring essential but ototoxic treatments. The findings also intersect with broader hearing health topics. For example, understanding chemical susceptibility may inform our knowledge of conditions like hyperacusis, where sound tolerance is altered.

The systemic nature of drug effects reminds us that auditory health is connected to overall physiology. Stress and systemic inflammation, discussed in contexts like PTSD and tinnitus, can influence vulnerability. Furthermore, the importance of integrated care is underscored by research on conditions such as temporomandibular disorders and ear symptoms, where multiple systems interact.

Just as managing chronic conditions often requires a holistic view—evident in approaches for improving sleep in the context of depression—protecting hearing may depend on understanding drug interactions across the entire body.

Source: The research discussed in this article is based on the paper “A computational pipeline for the systematic mapping of ototoxic and otoprotective compounds” by del Moral-Morales, A., Arguello‐Camarillo, J., & Castañón Bello, J. Y. (2026). Frontiers in Drug Discovery. The full paper is available via DOI: 10.3389/fddsv.2026.1834905.